Short answer
ARDELYX, INC. (ARDX) filed its Q3 2026 10-Q quarterly report on Nov 3, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $128M (up 15.7% year over year) with net income of −$737,000.
Q3 2026 key financials · XBRL
- Revenue
- $128M
- +15.7% YoY · +5.6% QoQ
- Net income
- −$737,000
- +23.9% YoY · +95.6% QoQ
- Operating margin
- 3.2%
- EPS (diluted)
- $0.00
- +100.0% QoQ
Source: XBRL data from the ARDELYX, INC. (ARDX) Q3 2026 10-Q on SEC EDGAR. USD.
ARDELYX, INC. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $127.655M vs $110.329M, up $17.326M YoY
- GTN adjustment rate 31.7% vs 30.6%; unfavorable channel mix and higher rebate charges
- Best performer IBSRELA sales $96.286M vs $78.158M; XPHOZAH sales $29.169M vs $27.357M
- Liquid funds $285.338M vs $264.689M; Term F Loan added $50.0M
- Operating cash use $36.465M, down from $63.434M; outlook funds operations at least one year
Risk Factors
- New regulatory risk: March 27, 2026 CMS guidance expects ESRD facilities to furnish XPHOZAH under bundled payment
- Most material update: June 26, 2026 appellate dismissal upheld XPHOZAH’s ESRD PPS challenge
- Operational risk: Three manufacturing stages rely on single-source CMOs with no qualified alternatives
- Financial risk: $200.0 million outstanding principal under SLR term loans as of September 30, 2026
- Competitive risk: At least four phosphate binders remain in development, including two Phase 3 programs
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ARDELYX, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.